




STINGRAY
THERAPEUTICS

**Developing the Next
Generation Of
Immunotherapy To
Combat Cancer**

ENPP1 IS THE ONLY KNOWN CHECKPOINT OF INNATE IMMUNITY







HIGH ENPP1 causes:

- Reduced immune infiltration
- Increased metastasis
- Tumors resistant to immuno- and chemo-therapy



[Cancer Discov.](#) 2020 Dec 28;CD-20-0387.
[Nature Cancer](#) volume 1, pages184–196(2020)
[Nat Commun.](#) 2018 Oct 24;9(1):4424.
[Nat Chem Biol.](#) 2014 Dec;10(12):1043-8

ENPP1 EXPRESSION AND IMMUNE SUPPRESSION IN HUMAN CANCER



Cancer Discov. 2020 Dec 28;CD-20-0387.
 Nature Cancer volume 1, pages184–196(2020)
 Nat Commun. 2018 Oct 24;9(1):4424.
 Nat Chem Biol. 2014 Dec;10(12):1043-8

LOSS OF ENPP1 SENSITIZES TUMORS TO IMMUNE CHECKPOINT BLOCKADE




4T1 syngeneic mouse model of triple negative breast cancer
Highly resistant to checkpoint inhibitor

Cancer Discov. 2020 Dec 28;CD-20-0387.
Nature Cancer volume 1, pages184–196(2020)


DEVELOPMENT OF SR-8541A AS A POTENT AND SELECTIVE INHIBITOR OF ENPP1

Potency

ENPP1 enzymatic assay




ENPP1 Thermal Shift Assay (1 μg hENPP1/well)




Selectivity

ENPP2 enzymatic assay



Cell-based ENPP enzymatic assay







	hENPP1	hENPP3	mENPP1
IC50	0.06217	18.80	0.9865


- 0/6 hits in p450 Enzyme panel at 10 μM
- 39.9 μM against hERG
- 0/468 hits at 1 μM in Kinome Panel
- 0/13 hits at 1 μM PDE panel
- 0/40 hits in 1 μM Bromodomain Panel
- 0/168 hits the GPCR Panel at 10 μM



LOW DOSES OF SR-8541A SHOW SINGLE AGENT EFFECT IN A COLON CANCER MODEL (CT-26)







SR-8541A ENHANCES THE EFFECT OF CHECKPOINT INHIBITION




Treatment with SR-8541A in a breast cancer organoid model shows increased immune infiltration and enhances the effect of checkpoint based immuno-therapies.

SR-8541A COMBINED WITH FC-ENHANCED CTLA-4 ANTIBODY SHOWS STRONG EFFECT IN CT-26 COLON CANCER MODEL





COMBINATION WITH SR-8541A +/- FC-ENHANCED ANTI-CTLA-4 +/- ANTI-PD-1



HIGH ENPP1: LOW RESPONSE TO CHECKPOINT INHIBITORS AND IMPAIRED SURVIVAL


Clinical Response Rate to Checkpoint Inhibition in cGAS High/ENPP1 High Expressing Tumor Types



Response to therapy:

- BRCA – Breast Cancer
- TGCT – Tenosynovial giant cell tumor
- SARC - Sarcoma
- **PAAD – Pancreatic adenocarcinoma**
- MESO - Mesothelioma
- **READ – Renal cell adenocarcinoma**
- STAD – Stomach adenocarcinoma
- **COAD – Colon adenocarcinoma**
- KIRC – Kidney renal clear cell carcinoma
- ESCA – Esophageal carcinoma
- OV – Ovarian cancer
- LUAD – Lung adenocarcinoma cancer

A NEW STANDARD OF CARE FOR MSS COLORECTAL CANCER



In Phase 2/3 development by Agenus

- Adaptive immune therapies
- Checkpoint inhibitors (Bot + Bal)
- 23% response in patients **without** liver metastasis
- 7% response in patients **with** liver metastasis

Stingray's ENPP1 inhibitor + Bot/Bal

- Addition of an innate immune therapy
- ENPP1 is upregulated in metastatic disease
- Active collaboration with Agenus to supply Bot/Bal for upcoming trials
- Tremendous investigator enthusiasm at major cancer centers

A TEAM OF OUTSTANDING BIOTECH SPECIALISTS



Jon Northrup MBA
Co-Founder
Chief Executive Officer



Sunil Sharma MD, FACP, MBA
Co-Founder
Chief Medical Officer



Uma Bhatt CPA
Chief Financial Officer



Mohan Kaadige PhD
Head, Biology



Srinivas Kasibhatla PhD
Head, Chemistry



Monil Shah PharmD, MBA
Chief Development Officer



Alexis Weston
Director, BD & Program Management



Rend Williams MPH, PMP
Head, Clinical Development



Linda McBride RPh, RAC
Director, Regulatory



Trason Thode
Manager, Biology



VALIDATION AND AWARD SUPPORT OF THE PROGRAM

Cancer Prevention and Research Institute of Texas (CPRIT) \$14M 3-year award

- Term of December 1, 2023, to November 30, 2026
- Covers 2/3rds of expenses in the MSS CRC trial (sites, CRO, drug supply, etc.)
- Covers ½ of company overhead & other expenses
- 34 applicants tried; 5 awards received



National Cancer Institute Direct to Phase 2 \$2M 2-year grant

- Term of September 15, 2022, to September 15, 2024
- Paid/pays for accepted IND, toxicology, pharmacology, CMC and preclinical efficacy experiments throughout most of 2024
- Received first try, start accelerated 3 months

NATIONAL
CANCER
INSTITUTE

SBIR
DEVELOPMENT CENTER

VALIDATION FROM IMPACT INVESTORS

GKCC Family Office (Miami)

- Two investments
- Focus to cure cancer
- Dean Krauss, Advisor & Board Member

Springhood Ventures (Boston)

- Impact investing arm of the Charles H Hood Foundation
- Looks to fill gaps in medical innovation funding to springboard new therapies

Catalytic Impact Foundation

- Two investments
- Accelerate Breakthroughs by Funding Extraordinary Innovations by Visionary Leaders



TRACTION

- **First company to start ENPP1 inhibitors for cancer (2016)**
- **Close to exit and capital efficient**
 - Only 40 months of clinicals left
 - Sale to a big pharma in clinicals
- **Big potential**
 - **Could be a new standard of care in microsatellite stable colorectal cancer**
 - Broad application across many tumors (~ 1/2 of all tumors) with checkpoint inhibitors
- **Tremendous Grants and Awards Received - \$16M**
- **Notable Investors in the program**
 - Venture – GPG Ventures (Dallas), Springhood Ventures (Boston), HonorHealth Ventures (Phoenix), Early Investment Partners (NJ)
 - Angels – Keiretsu NW, Northern Cal, Mumbai; US Angels (Palo Alto), PP Capital (Dallas) Landmark Angels (NY), Backseat Drivers (Phoenix)



A major impact drug that may change lives.



Join a proven team that's repeating their model.

#1

A leading program.

jon@stingraytx.com

+1 317 517 9500